生物谷原董事长林艳和获刑三年，缓刑请求被驳回 经济观察网 杜远/文 因将上市公司生物谷(920266.BJ)的资金违规违法转至深圳金沙江投资有限公司(下称"金沙江投资")，生 物谷原实际控制人、董事长林艳和获刑三年，二审法院驳回了缓刑请求。 12月22日晚，生物谷公告披露，林艳和原系生物谷法定代表人和实际控制人，时任生物谷董事长兼总经 理，同时亦是金沙江投资的实际控制人。为满足金沙江投资资金需求，2021年8月27日至2022年3月11 日，林艳和安排时任生物谷董事会秘书兼财务总监贺元，违反上市公司财务管理制度、未在生物谷按规 定召开总经理办公会和未经公司投资评审小组审议的情况下，隐瞒资金真实用途，利用生物谷投资理财 决议，虚构委托第三方机构理财的事实，将生物谷及子公司的自有资金转至多家外部公司， 2020年7月，精选层敲钟开市，首批32家企业晋层交易。时任生物谷董事长林艳和在媒体上发出"寄 语"："精选层将是中国价值创新、价值创造中不可缺少的一个内核。生物谷也将为精选层、为我国资本 市场中国价值的展现，点亮一束光，贡献一份热。" 然而，不到两年后情势直转。2022年5月11日，林艳和因涉嫌信息披露违法违规被 ...

Core Viewpoint - The company, Zhejiang Shapuaisi Pharmaceutical Co., Ltd., has responded to the Shanghai Stock Exchange's inquiry regarding its 2024 annual report, particularly focusing on its investment in Shanghai Xinhong Pharmaceutical Co., Ltd. and the acquisition of shares in Yunnan Biological Valley Pharmaceutical Co., Ltd. [1][2] Investment in Shanghai Xinhong - The company, along with partners, invested a total of 460 million yuan in Shanghai Xinhong, with the company contributing 160 million yuan for a 34.7% stake [1][2] - The investment aims to leverage synergies between the company and Yunnan Biological Valley, which specializes in traditional Chinese medicine, particularly in cardiovascular disease treatments [2][4] Financial Performance of Yunnan Biological Valley - Yunnan Biological Valley reported revenues of 587 million yuan, 622 million yuan, and 516 million yuan over the last three years, with net losses of 49 million yuan, 12 million yuan, and 74 million yuan respectively [1][2] - The company recognized an investment loss of 7.22 million yuan related to its stake in Shanghai Xinhong due to Yunnan Biological Valley's losses in 2024 [1][2] Market Context - The increasing prevalence of cardiovascular diseases in China, with 330 million patients reported, highlights a growing market for related pharmaceuticals, particularly traditional Chinese medicine [4][3] - The company anticipates significant growth in the market for cardiovascular traditional Chinese medicine products, driven by an aging population and rising health awareness [4][3] Internal Decision-Making and Compliance - The company asserts that its investment decisions followed internal procedures compliant with the Company Law and relevant regulations, and the investment amount did not exceed 10% of its audited net assets [11][12] - Independent directors have confirmed that the investment process was conducted properly and did not harm the interests of the company or its minority shareholders [11][12] Other Investments - As of the end of 2024, the company reported long-term equity investments totaling 307 million yuan and other non-current financial assets of 20.4 million yuan, with additional investments in various pharmaceutical companies [12][15] - The company has engaged in risk investments, purchasing stocks worth 1.079 billion yuan and selling stocks worth 940 million yuan, resulting in a loss of 25 million yuan [12][15]